Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Non-Current Deffered Revenue data on record, last reported at $8.6 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue rose 3.22% year-over-year to $8.6 million; the TTM value through Sep 2025 reached $8.6 million, up 3.22%, while the annual FY2023 figure was $33.1 million, 10.26% down from the prior year.
  • Non-Current Deffered Revenue reached $8.6 million in Q3 2025 per STOK's latest filing, down from $9.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $49.5 million in Q1 2022 and bottomed at $8.3 million in Q3 2024.
  • Average Non-Current Deffered Revenue over 4 years is $28.8 million, with a median of $33.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 79.64% in 2024, then rose 3.22% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $36.9 million in 2022, then fell by 10.26% to $33.1 million in 2023, then crashed by 74.93% to $8.3 million in 2024, then rose by 3.22% to $8.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $8.6 million in Q3 2025, $9.6 million in Q2 2025, and $10.3 million in Q1 2025.